December 2025 — ALK Positive is proud to announce a new partnership with Pfizer to address a critical gap in patient and caregiver education for those navigating advanced ALK-positive non-small cell lung cancer (NSCLC). Together, we are launching a Request for Proposals (RFP) to support independent medical education (IME) projects designed to enhance understanding, confidence, and quality of life for individuals facing an ALK+ diagnosis.
This collaboration reflects a shared commitment to meeting the real-world needs of patients and care partners — especially as treatment landscapes evolve and targeted therapies continue to transform outcomes.
Full RFP link: Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC)
Why This Matters
People diagnosed with advanced ALK+ NSCLC are often thrust into a complex treatment journey. ALK inhibitors have dramatically improved outcomes, but patients and families still report uncertainty in several areas:
- What to expect when starting ALK inhibitor therapy
- How to recognize early side effects
- How and when to engage with healthcare teams
- How to balance treatment with quality of life
- How to make decisions aligned with personal goals and preferences
Education is one of the most powerful tools we can offer. When people understand their treatment, feel equipped to discuss symptoms, and have access to clear, accessible resources, they are better able to advocate for themselves — and live well.
This RFP is designed to fuel creative, high-impact solutions that directly address those needs.
What This Grant Opportunity Supports
Organizations are invited to submit proposals for independent projects that advance patient and caregiver education in the ALK+ community. Areas of focus include:
1. Preparing patients and care partners for ALK inhibitor therapy
Resources that explain what treatment entails, expected side effects, and how to communicate effectively with care teams.
2. Tools for early side-effect recognition and quality-of-life support
Materials that help patients identify symptoms early and make lifestyle adjustments that support overall well-being.
3. Resources that elevate patient preferences and accessibility
Decision aids, multilingual tools, inclusive education models, and approaches that ensure all patients — regardless of background, language, or health literacy — can fully engage in their care.
Proposals may take many forms, such as:
- Plain-language patient toolkits
- Digital or interactive learning tools
- Symptom-preparedness guides
- Multidisciplinary communication resources
- Innovative education formats designed with patients in mind
(Please note: this opportunity supports independent medical education; Pfizer and ALK Positive will not be involved in developing, implementing, or conducting funded projects.)
Key Information
- RFP Release Date: December 3, 2025
- Application Deadline: February 18, 2026
- Geographic Scope: North America, South America, Europe, and Australia
- Funding: Individual projects up to $100,000
- Eligible Applicants: Academic institutions, healthcare systems, patient advocacy organizations, medical societies, and medical education companies
Full eligibility criteria, submission instructions, and proposal requirements are included in the RFP linked here.
Our Shared Vision
As a patient-founded organization, ALK Positive has always believed in the power of knowledge. Education is not simply information — it is empowerment, clarity, and hope. We are grateful to partner with Pfizer in offering this meaningful opportunity to organizations that share this mission.
By supporting independent educational projects, we aim to ensure that people living with ALK+ lung cancer — and the families walking beside them — have the tools, confidence, and understanding they need from the very start of their treatment journey.
We look forward to seeing innovative proposals that uplift and strengthen our community.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com).
